NCT02654028 (AT/HCC) is a NA clinical trial of Autotransfusion in Liver Cancer, sponsored by Guangxi Medical University.

Who is sponsoring NCT02654028?

NCT02654028 is sponsored by Guangxi Medical University.

What drugs are being tested in NCT02654028?

Interventions in NCT02654028: Autotransfusion, Control group.

What condition does NCT02654028 study?

NCT02654028 studies Liver Cancer.

Is NCT02654028 still recruiting?

NCT02654028 is currently completed. Last updated 25 January 2023.

Last reviewed 2023-01-25 · How we verify

NCT02654028: AT/HCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association Between Autologous Transfusion and Recurrence-free Survival in Patients With HCC After Resection

Completed NA Last updated 25 January 2023

What this trial tests

NA trial testing Autotransfusion in Liver Cancer in 618 participants. Completed in 30 December 2021.

Timeline

5 January 2019

Primary endpoint
30 December 2021

30 December 2021

Quick facts

Lead sponsor	Guangxi Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	618
Start date	5 January 2019
Primary completion	30 December 2021
Estimated completion	30 December 2021
Sites	1 location across China

Drugs / interventions tested

Autotransfusion
Control group — full drug profile →

Conditions studied

Liver Cancer — all drugs for Liver Cancer →

Sponsor

Guangxi Medical University

Who can join

Adults 18 to 75, any sex, with Liver Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective non-randomized controlled trial aims to determine whether autotransfusion of red blood cells salvaged before liver resection is associated with the recurrence-free survival in patients with hepatocellular carcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery.
Lloyd TD, Geneen LJ, Bernhardt K, McClune W, et al · · 2023 · cited 20× · PMID 37681564 · DOI 10.1002/14651858.cd001888.pub5

Verify or expand the search:

Other trials of Autotransfusion

Trials testing the same drug.

NCT06425614 — COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial · NA · recruiting
NCT05612477 — Blood Salvage in Orthotopic Liver Transplantation With HCC · NA · active not recruiting

Other recruiting trials for Liver Cancer

Currently open trials in the same condition.

NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting

Other Guangxi Medical University trials

Trials by the same sponsor.

NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT06851104 — A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence · Phase 2 · terminated
NCT05711823 — Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC · Phase 3 · unknown
NCT05910970 — Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation · Phase 3 · unknown
NCT06161272 — Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02654028 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangxi Medical University
Last refreshed: 25 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02654028.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing